Explore insights and strategies for managing ATTR-CM long-term.
-
-
New study calls for more inclusive patient data in rare disease research
-
Coramitug obtains Fast Track designation for ATTR-CM
-
Slow doesn’t mean stop
-
TTR stabilizer therapy increases naturally occurring antibodies in ATTR-CM
-
Acoramidis shows sustained benefits in ATTR-CM at 54-month follow-up
-
New study sheds light on patients’ experiences in ATTR care